Clearline Capital’s Vir Biotechnology VIR Stock Holding History

Clearline Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-44,097	Closed	-$1.85M	–	161
2021 Q4	$1.85M	Buy	+44,097	New	+$1.73M	0.2%	75

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Clearline Capital's VIR Position: Q1 2022 in Review

Clearline Capital sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 44,097 shares — an estimated $1.85M sold.

Clearline Capital first reported a position in VIR in Q4 2021 and held it in 1 quarter. The position peaked at $1.85M in Q4 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

Clearline Capital reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
Clearline Capital sold 44,097 Vir Biotechnology shares in Q1 2022, an estimated $1.85M.
Clearline Capital first reported a position in Vir Biotechnology in Q4 2021 and held it in 1 quarter.
Clearline Capital's Vir Biotechnology position peaked at $1.85M in Q4 2021.
204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Clearline Capital's 13F filing for Q1 2022, filed 16 May 2022.